Trial Profile
A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 16 Nov 2023 Planned End Date changed from 21 May 2020 to 30 Nov 2025.
- 16 Nov 2023 Planned primary completion date changed from 21 May 2020 to 30 Nov 2025.
- 19 Nov 2019 Planned End Date changed from 30 Nov 2020 to 21 May 2020.